Zacks Research Weighs in on Masimo FY2027 Earnings

Masimo Co. (NASDAQ:MASI - Free Report) - Research analysts at Zacks Research issued their FY2027 EPS estimates for shares of Masimo in a note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will post earnings of $6.61 per share for the year. The consensus estimate for Masimo's current full-year earnings is $4.10 per share.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million.

MASI has been the subject of a number of other reports. Wells Fargo & Company upped their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler raised their target price on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Finally, Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $194.80.

Remove Ads

Masimo Trading Up 1.1 %

MASI stock traded up $1.79 during midday trading on Thursday, reaching $167.61. 520,030 shares of the company's stock traded hands, compared to its average volume of 626,240. The business has a 50-day moving average price of $175.03 and a two-hundred day moving average price of $160.20. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market capitalization of $9.04 billion, a P/E ratio of 115.59 and a beta of 1.04.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently modified their holdings of MASI. Jefferies Financial Group Inc. bought a new stake in Masimo in the fourth quarter valued at about $1,762,000. Forum Financial Management LP acquired a new position in shares of Masimo in the 4th quarter worth approximately $217,000. Pacific Point Advisors LLC bought a new stake in shares of Masimo in the 4th quarter valued at approximately $208,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Masimo by 69.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 190,246 shares of the medical equipment provider's stock valued at $31,448,000 after acquiring an additional 77,775 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in Masimo by 450.4% during the fourth quarter. Woodline Partners LP now owns 51,185 shares of the medical equipment provider's stock worth $8,461,000 after purchasing an additional 41,885 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Insiders Place Their Bets

In related news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.